Clinical Trials Logo

Dry Eye Syndromes clinical trials

View clinical trials related to Dry Eye Syndromes.

Filter by:

NCT ID: NCT04091581 Completed - Evaporative Dry Eye Clinical Trials

Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye

BULLDOG
Start date: November 21, 2019
Phase: Phase 4
Study type: Interventional

The objective of the study is to compare the rate of tear evaporation, measured with a novel evaporimeter, before and for one hour after an eye drop containing nano-sized oil droplets has been instilled.

NCT ID: NCT04084483 Completed - Dry Eye Disease Clinical Trials

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

Start date: August 4, 2019
Phase: Phase 2
Study type: Interventional

The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.

NCT ID: NCT04081610 Completed - Dry Eye Clinical Trials

Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution

PRO-037
Start date: September 9, 2019
Phase: Phase 1
Study type: Interventional

Study design: Phase I clinical trial, single-center, controlled, parallel group, open, randomized. Number of subjects: n = 34 evaluable subjects, 17 evaluable subjects per group (both eyes). Estimated duration of the study: 5 months Therapeutic indication: Eye lubricant Use: Dry Eye Objective:To evaluate the safety and tolerability of Lagricel® Ofteno multidose manufactured by Laboratorios Sophia on the ocular surface of clinically healthy subjects. Hypothesis: H0 = Lagricel® Ofteno multidose ophthalmic solution has a safety and tolerability profile similar to Lagricel® Ofteno single dose in healthy subjects. H1 = Lagricel® Ofteno multidose ophthalmic solution has a different safety and tolerability profile than Lagricel® Ofteno single dose in healthy subjects. Main inclusion criteria: Clinically healthy subjects

NCT ID: NCT04063735 Completed - Dry Eye Clinical Trials

Alleviating Effects Against Dry Eye by Oral Intake of Cordyceps Cicadae Mycelia

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

Cordyceps cicadae mycelia was tested for amelioration of dry eye symptoms through dietary supplementation. Its efficacy in relief of human dry eye status was assessed by randomized, double-blinded tests, including multiple assessments. The results were compared between the placebo group and the experimental group.

NCT ID: NCT04063644 Completed - Cataract Clinical Trials

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Start date: May 30, 2019
Phase: N/A
Study type: Interventional

Clinical trial with medical devices, post-authorization, parallel, single-blind, randomized, comparative, prospective to study how afects the quality of life the use of ocular eye drops on patients with dry eye symptomatology and age-related loss of visual acuity. Secondary purposes: efects on the dry eye symptomatology, efect on visual acuity and treatment adherence.

NCT ID: NCT04043949 Completed - Dry Eye Clinical Trials

The Influences of Dry Eye Disease on Optical Quality

Start date: July 1, 2017
Phase:
Study type: Observational

DED could result in visual disturbance and damage optical quality. We aimed to evaluate the influences of dry eye disease (DED) on optical quality and their correlations.

NCT ID: NCT04036292 Completed - Clinical trials for Dry Eye Disease (DED)

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Start date: July 23, 2019
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.

NCT ID: NCT04030962 Completed - Dry Eye Disease Clinical Trials

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

This will be a 2 stage study in which Stage 1 will evaluate the safety of AGN-242428 and AGN-231868, how well they are tolerated and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 will begin. Stage 2 will also evaluate the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in treating dry eye disease and assess the plasma and tear exposure of both ophthalmic solutions.

NCT ID: NCT04025801 Not yet recruiting - Hypertension Clinical Trials

Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals

Start date: July 31, 2019
Phase:
Study type: Observational

In vivo confocal microscopy (IVCM) has been used in clinical settings for more than 25 years, and is noninvasive, rapid and easily repeatable technique to investigate ocular surface disorders. It enables morphological and quantitative analysis of ocular surface microstructure. [1-3] As the technology advances, new IVCM machine, Heidelberg Retinal Tomograph with Rostock Corneal Module (HRT-RCM), was developed. Hardware and software modifications and acquisition techniques continue to expand the applications of the HRT-RCM for quantitative in vivo corneal imaging at the cellular level. The new software can access the corneal nerve more accurate. Here the investigators proposed this Institutional Review Board (IRB) to collect healthy persons and cases of different systematic diseases as well as etiologies of ocular surface diseases.

NCT ID: NCT04022382 Completed - Dry Eye Clinical Trials

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

Start date: July 18, 2019
Phase: N/A
Study type: Interventional

A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with 0.1ml Restylane Defyne and the other eye injected with 0.2ml Restylane Defyne. Participants will be evaluated over four visits.